Targeted tuberculosis contact investigation saves money without sacrificing health

Journal of Public Health Management and Practice

Volumn 15, Issue 4, 2009, Pages 319-327

  Pisu, Maria ^a   Gerald, Joe ^b,c   Shamiyeh, James E ^d   Bailey, William C ^a   Gerald, Lynn B ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE CONTROL; HEALTH CARE COST; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SKIN TEST; TUBERCULOSIS;

ADULT; AGED; ALABAMA; CONTACT TRACING; COST-BENEFIT ANALYSIS; DECISION TREES; EFFICIENCY, ORGANIZATIONAL; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ORGANIZATIONAL; MYCOBACTERIUM TUBERCULOSIS;

EID: 67650935348     PISSN: 10784659     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHH.0b013e31819c3ef2     Document Type: Article

References (30)

1. Comstock GW. Epidemiology of tuberculosis. In: Reichman L, Hershfield HE, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York, NY: Marcel Dekker; 2000:129-156.
2. Reichler MR, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of Tuberculosis. JAMA. 2002;287:991-995.
3. Cohn DL, El-Sadr WM. Treatment of latent tuberculosis infection. In: Reichman L, Hershfield HE, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York, NY: Marcel Dekker; 2000:471-502.
4. Etkind S, Veen J. Contact follow-up in high- and low- prevalence countries. In: Reichman L, Hershfield HE, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York, NY: Marcel Dekker; 2000:377-399.
5. National Tuberculosis Controllers Association; Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54:1-47.
6. Gerald LB, Tang S, Bruce F, et al. A decision tree for tuberculosis contact investigation. Am J Respir Crit Care Med. 2002;166:1122-1127.
7. Bailey WC, Gerald LB, Kimerling ME, et al. Predictive model to identify positive tuberculosis skin test results during contact investigations. JAMA. 2002;287:996-1002.
8. Menzies R. Tuberculin skin testing. In: Reichman L, Hershfield HE, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York, NY: Marcel Dekker; 2000:279-322.
9. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States. Int J Tuberc Lung Dis. 2003;7(12 suppl 3):S384-S390.
10. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137:215-220.
11. Rose DN, Schechter CB, Silver AL. The age threshold for iso- niazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. JAMA. 1986;256:2709-2713.
12. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978;117:991-1001.
13. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med. 1997;127:1051-1061.
14. Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemo- prophylaxis. Am J Prev Med. 1988;4:102-109.
15. Jasmer RM, Snyder DC, Saukkonen JJ, et al. Short-course ri- fampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis. 2004;38:363-369.
16. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014-1018.
17. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935-952.
18. Arias E. United States life tables, 2001. Natl Vital Stat Rep. 2004;52:1-38.
19. American Thoracic Society. Medical Section of the American Lung Association: treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis. 1986;134:355-363.
20. Hansel NN, Merriman B, HaponikEF, Diette GB. Hospitaliza- tions for tuberculosis in the United States in 2000: predictors of in-hospital mortality. Chest. 2004;126;1079-1086.
21. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28-106.
22. Taylor Z. The cost-effectiveness of screening for latent tuberculosis infection. Int J Tuberc Lung Dis. 2000;4:S127-S133.
23. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med. 1995;155:1595-1600.
24. Menzies D, Oxlade O, Lewis M. Costs for Tuberculosis Care in Canada. Ottawa: Public Health Agency of Canada; 2006. http://www.phac-aspc. gc.ca/tbpc-latb/costtb/index-eng. php. Published 2006. Accessed November 1,2008.
25. Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int] Tuberc Lung Dis. 2000;4:931- 939.
26. University of Alabama and Alabama Department of Public Health. Tuberculosis Primer. Birmingham: University of Alabama/Montgomery. Alabama Department of Public Health; 2004.
27. Gerald LB, Bruce F, Brooks CM, et al. Standardizing contact investigation protocols. IntJ Tuberc Lung Dis. 2003;7(12):S369-S374.
28. Sprinson JE, Flood J, Fan CS, et al. Evaluation of tuberculosis contact investigations in California. Int J Tuberc Lung Dis. 2003;7(12):S363- S368.
29. Salpeter SR, Salpeter EE. Screening and treatment of latent tuberculosis among health care workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2004;25:1056-1061.
30. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am Respir Crit Care Med. 2000;162:2033-2038.